Tyra Biosciences (TYRA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Precision Medicinesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 55/100 (HIGH), 9.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 30.48% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value
- Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks
- Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat
- Tyra disappoints investors with bladder cancer data
- Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
- Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data
- Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Access to early-phase oncology trials: Trajectories and outcomes of more than 26,000 patients referred to a high-volume phase I unit. — Eur J Cancer 2026 Sep 17 PMID 42762559
- Reappraisal of Cisplatin vs Carboplatin Treatment for Solid Tumors: An Umbrella Meta-Analysis. — JAMA Netw Open 2026 Sep 1 PMID 42752909
- Long-acting growth hormone: an updated Growth Hormone Research Society consensus statement. — Eur J Endocrinol 2026 Aug 28 PMID 42676236
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma. — ESMO Open 2026 Aug PMID 42660571
- Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer. — Biomolecules 2026 Aug 17 PMID 42650864
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Tyra Biosciences.
Full TYRA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.